Results from World's Largest Study on Sleep Apnea and Digital Connected Care

Go back to Results from World's Largest Study on Sleep Apnea and Digital Connected Care

Jefferies Cuts Price Target on ResMed (RMD) to $56 Following 1Q Miss

October 26, 2016 7:11 AM EDT

Jefferies maintained an Underperform rating on ResMed (NYSE: RMD), and cut the price target to $56.00 (from $58.00), following the company's 1Q earnings report. ResMed reported a $10mn revenue miss on a $0.02 EPS miss. Organic growth of 3% drove EPS growth of 7%; however, excluding... More